- Home
- RXST vs BCYC Comparison
RXST vs BCYC Comparison
Compare RXST & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXST | BCYC |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.0M | 360.7M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RXST | BCYC |
|---|---|---|
| Price | $6.59 | $4.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 10 |
| Target Price | $11.60 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 620.4K | 490.2K |
| Earning Date | 05-06-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $134,479,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.57 | $37.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.02 | $4.25 |
| 52 Week High | $27.13 | $9.69 |
Technical Indicators
Market Signals| Indicator | RXST | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 39.55 |
| Support Level | N/A | N/A |
| Resistance Level | $9.11 | $7.71 |
| Average True Range (ATR) | 0.41 | 0.29 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 30.10 | 37.50 |
Price Performance
Historical ComparisonAbout RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.